EGFR基因突变非小细胞肺癌药物治疗对心脏影响

Cardiac effects of drug therapy for non-small cell lung cancer with EGFR gene mutation

非小细胞肺癌(Non-small-cell carcinoma,NSCLC)约占肺癌患者的85%,且发病率逐年增加,而分子靶向治疗的快速发展为晚期非小细胞肺癌的患者带来了希望。其中,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗非小细胞肺癌期间不可避免地会出现不同程度的心血管毒性。临床上在治疗非小细胞肺癌的同时,关注EGFR-TKI所致的心血管毒性是必要的。本文就EGFR-TKI治疗晚期非小细胞肺癌所导致的心血管毒性做出分析,以探索基于免疫疗法抑制剂治疗EGFR-TKI耐药非小细胞肺癌患者的重要临床研究,为更好地治愈非小细胞肺癌,并防治相关并发症提供参考。

Non-small cell lung cancer(NSCLC)accounts for about 85%of lung cancer patients,and the incidence is increasing year by year,while the rapid development of molecular targeted therapy has brought hope to patients with advanced non-small cell lung cancer.Among them,epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)in the treatment of non-small cell lung cancer will inevitably appear different degrees of cardiovascular toxicity.It is necessary to pay attention to the cardiovascular toxicity caused by EGFR-TKI in the treatment of non-small cell lung cancer.This paper analyzes the cardiovascular toxicity caused by EGFR-TKI in the treatment of advanced non-small cell lung cancer,and explores the important clinical studies based on immunotherapy inhibitors in the treatment of EGFR-TKI resistant NSCLC patients,so as to provide references for better cure of non-small cell lung cancer and prevention and treatment of related complications.